Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

PYC Therapeutics has built a pipeline of drug candidates addressing rare genetic diseases, with three assets now in clinical stages. The company’s strategy centers on using RNA therapeutics to ...

PYC Therapeutics Ltd. has announced the results of a study of PYC-003 conducted in human 3D models derived from patients with end-stage renal failure due to autosomal dominant polycystic kidney ...

The latest announcement is out from PYC Therapeutics Limited ( (AU:PYC)). PYC Therapeutics Limited has disclosed a change in director Peter Coleman’s interests, reporting the issue of 2,000,000 ...

View PYC Therapeutics Ltd stock forecast data, including PYC stock price estimates and 12-month PYC Therapeutics Ltd price targets, to assess potential upside or downside. Compare PYC analyst ratings ...

PYC Therapeutics Limited ( (AU:PYC)) has shared an announcement. PYC Therapeutics has issued 2,000,000 unlisted options to director Peter Coleman under an exception to ASX Listing Rule 10.12, with ...